当前位置: X-MOL 学术J. Clin. Invest. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2021 , DOI: 10.1172/jci155114
Katharine J Bar 1 , Pamela A Shaw 1, 2 , Grace H Choi 1 , Nicole Aqui 1 , Andrew Fesnak 1 , Jasper B Yang 1, 2 , Haideliza Soto-Calderon 1 , Lizette Grajales 1 , Julie Starr 1 , Michelle Andronov 1 , Miranda Mastellone 1 , Chigozie Amonu 1 , Geoff Feret 1 , Maureen DeMarshall 1 , Marie Buchanan 1 , Maria Caturla 1 , James Gordon 1 , Alan Wanicur 1 , M Alexandra Monroy 1 , Felicity Mampe 1 , Emily Lindemuth 1 , Sigrid Gouma 1 , Anne M Mullin 1 , Holly Barilla 1 , Anastasiya Pronina 1 , Leah Irwin 1 , Raeann Thomas 1 , Risa A Eichinger 1 , Faye Demuth 1 , Eline T Luning Prak 1 , Jose L Pascual 1 , William R Short 1 , Michal A Elovitz 1 , Jillian Baron 1 , Nuala J Meyer 1 , Kathleen O Degnan 1 , Ian Frank 1 , Scott E Hensley 1 , Donald L Siegel 1 , Pablo Tebas 1
Affiliation  

Background. Antibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia.

中文翻译:

一项针对住院 COVID-19 肺炎患者恢复期血浆的随机对照研究

背景。基于抗体的 COVID-19 策略在预防和治疗早期疾病方面显示出前景。COVID-19 恢复期血浆 (CCP) 已被广泛使用,但支持其对住院肺炎患者有益的随机试验结果有限。在这里,我们评估了 CCP 对患有 COVID-19 肺炎的重症住院成人的疗效。
更新日期:2021-12-15
down
wechat
bug